interchange of vaccine products; Covid-19 Immunisation; Suspected covid-19 infection/runny nose, cough, and weakness; This spontaneous case was reported by a patient and describes the occurrence of SUSPECTED COVID-19 (Suspected covid-19 infection/runny nose, cough, and weakness), INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Covid-19 Immunisation) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 005M51A and 071F21A) for COVID-19 prophylaxis.    Co-suspect products included non-company products COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis and NIRMATRELVIR, RITONAVIR (PAXLOVID) for COVID-19 treatment.    Concurrent medical conditions included Hypothyroidism and Drug allergy.   On 11-Mar-2021, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (unknown route) 1 dosage form. On 27-Oct-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-May-2022, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Jul-2022, the patient started NIRMATRELVIR, RITONAVIR (PAXLOVID) (unknown route) at an unspecified dose. In 2022, the patient experienced SUSPECTED COVID-19 (Suspected covid-19 infection/runny nose, cough, and weakness). On an unknown date, the patient experienced INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Covid-19 Immunisation). At the time of the report, SUSPECTED COVID-19 (Suspected covid-19 infection/runny nose, cough, and weakness) had not resolved and INTERCHANGE OF VACCINE PRODUCTS (interchange of vaccine products) and COVID-19 IMMUNISATION (Covid-19 Immunisation) outcome was unknown. Not Provided          No concomitant medications were reported.   It was unknown whether patient had any adverse event following dose 1 and 2. On 16-Jul-2022, 2 days after completing Paxlovid, the patient experienced runny nose, cough, and weakness. Reporter assessed causality for event suspected COVID-19 with Janssen vaccine as possibly related. The patient was not taking any other medications/products with in 2 weeks of starting COVID-19 treatment.  No treatment details were reported.  Company Comment: This is a spontaneous case concerning  a patient of unknown age and gender with no relevant medical history, who experienced the unexpected non-serious event of (AESI) Suspected Covid-19 and additional events of Covid-19 immunization and interchange of vaccine products. The events Covid-19 immunization and interchange of vaccine products occurred approximately 7 months after the after the first dose of Janssen Covid-19 Vaccine. It was reported event suspected covid-19 occurred approximately 2 months after the third dose of mRNA-1273 Vaccine. It was also reported patient took Paxlovid for 5 days, then after 2 days of completion of Paxlovid patient experienced the event Suspected covid-19. No further details on lab test results and further treatment received were reported. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.; Sender's Comments: This is a spontaneous case concerning  a patient of unknown age and gender with no relevant medical history, who experienced the unexpected non-serious event of (AESI) Suspected Covid-19 and additional events of Covid-19 immunization and interchange of vaccine products. The events Covid-19 immunization and interchange of vaccine products occurred approximately 7 months after the after the first dose of Janssen Covid-19 Vaccine. It was reported event suspected covid-19 occurred approximately 2 months after the third dose of mRNA-1273 Vaccine. It was also reported patient took Paxlovid for 5 days, then after 2 days of completion of Paxlovid patient experienced the event Suspected covid-19. No further details on lab test results and further treatment received were reported. The benefit-risk relationship of mRNA-1273 Vaccine, is not affected by this report.